Diletta Loschi

Dr. Diletta Loschi


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in The Journal of Cardiovascular Surgery
Verified
Journal Article
Closed access
DLDiletta Loschi
Diletta Loschi
AMAndrea Melloni
Andrea Melloni
AKAndrea Kahlberg
Andrea Kahlberg
RCRoberto Chiesa
Roberto Chiesa
GMGermano Melissano
Germano Melissano
Article: Kidney protection in thoracoabdominal aortic aneurysm surgery - The Journal of Cardiovascular Surgery 2021 August;62(4):326-38 - Minerva Medica - Journals

10 August 2023 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
DLDiletta Loschi
Diletta Loschi
ASAnnarita Santoro
Annarita Santoro
EREnrico Rinaldi
Enrico Rinaldi
CAClaudia Anselmi
Claudia Anselmi
CGCamilla Grignani
Camilla Grignani
GMGermano Melissano
Germano Melissano

19 July 2020 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
LBLuca Bertoglio
Luca Bertoglio
DLDiletta Loschi
Diletta Loschi
AGAlessandro Grandi
Alessandro Grandi
AMAndrea Melloni
Andrea Melloni
VBVictor Bilman
Victor Bilman
RCRoberto Chiesa
Roberto Chiesa

1 May 2023 in International Angiology
Verified
Journal Article
Closed access
DLDiletta Loschi
Diletta Loschi
ASAnnarita Santoro
Annarita Santoro
EREnrico Rinaldi
Enrico Rinaldi
GMGermano Melissano
Germano Melissano
Article: Renal perfusion in complex abdominal aortic aneurysm open repair: a scoping review - International Angiology 2023 June;42(3):223-8 - Minerva Medica - Journals

3 February 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Yamume TshombaYamume Tshomba
Yamume Tshomba
DOMENICO BACCELLIERIDOMENICO BACCELLIERI
DOMENICO BACCELLIERI
NCNiccolò Carta
Niccolò Carta
GCGiuseppe Cilli
Giuseppe Cilli
VAVincenzo Ardita
Vincenzo Ardita
RCRoberto Chiesa
Roberto Chiesa
Background: Plaque composition may predict the evolution of carotid artery stenosis rather than its sole extent. The grey scale median (GSM) value is a reproducible and standardized value to report plaque echogenicity as an indirect measure of its composition. We monitored plaque composition in asymptomatic subcritical carotid stenosis and evaluated the effect of an oral modulating calcification factor (vitamin K2). Methods: Carotid plaque composition was assessed by GSM value. Monitoring the effects of standard therapy (acetylsalicylic acid and low–medium dosage statin) (acetylsalicylic acid (ASA) arm) or standard therapy plus vitamins K2 oral supplementation (ASA + K2 arm) over a 12 months period was conducted using an ultrasound scan in a prospective, open-label, randomized controlled trial (PLAK2). Results: Sixty patients on low–medium dosage statin therapy were enrolled and randomized (30 per arm) to either ASA + K2 or ASA alone. Thirty-seven patients (61.6%) showed at 12 months a stable plaque with a mean increase in the GSM value in respect to the baseline of 2.6% with no differences between the two study arms (p = 0.66). Fifteen patients (25%) showed an 8% GSM value reduction respect the baseline with no differences between the two study arms (p = 0.99). At multivariable analysis, the adjusted mean (95% confidence interval) GSM change per month from baseline was greater in the ASA + K2 arm (−0.55 points, p = 0.048) compared to ASA alone (−0.18 points, p = 0.529). Conclusions: Carotid plaque composition monitoring through GSM value represents a laborious procedure. Although its use may not be applied to everyday practice, a specific application consists in evaluating the effect of pharmacological therapy on plaque composition. This 12 months randomized trial showed that the majority of subcritical asymptomatic carotid plaque on treatment with low–medium dosage statin presented a stable or increased echogenicity. Although vitamin K2 beyond standard therapy did not determine a significant change in plaque composition, for those who presented with GSM reduction it did enhance a GSM monthly decline.

Verified
Journal Article
Open access
PDF file
DLDiletta Loschi
Diletta Loschi
EREnrico Rinaldi
Enrico Rinaldi
ASAnnarita Santoro
Annarita Santoro
NFNicola Favia
Nicola Favia
NGNicola Galati
Nicola Galati
GMGermano Melissano
Germano Melissano
Introduction: This systematic review aims to analyze the current literature regarding 30-day mortality and postoperative acute kidney disease (AKI) in complex abdominal aortic aneurysms (cAAAs), which included juxtarenal aortic aneurysm (JAA), suprarenal aortic aneurysm (SRAA), and type IV thoracoabdominal aortic aneurysm (TAAA) open surgery (OS), to evaluate the impact of renal perfusion on AKI and to try to define which is the best way to perform it. Methods: A literature search in PubMed and Cochrane Library was performed, and articles published from January 1986 to January 2024 reporting on JAA, SRAA, and TAAA type IV open surgery management were identified. Multicenter studies, single-center series, and case series with ≥10 patients were considered eligible. Comparisons of outcomes of patients who underwent OS for complex abdominal aortic aneurysms (cAAAs) with or without perfusion of the renal arteries were analyzed when available. The titles, abstracts, and full texts were evaluated by two authors independently. The primary outcomes included AKI and 30-day mortality rates. The new-onset dialysis rate was considered a secondary outcome. Results: A total of 295 articles were evaluated, and 21 were included, totaling 5708 patients treated for cAAAs with OS. The male patients totaled 4094 (71.7%), with a mean age of 70.35 ± 8.01 and a mean renal ischemia time of 32.14 ± 12.89 min. Data were collected and analyzed, at first in the entire cohort and then divided into two groups (no perfusion of the renal arteries—group A vs. selective perfusion—group B), with 2516 patients (44.08%) who underwent cAAAs OS without perfusion of the renal arteries and 3192 patients (55.92%) with perfusion. In group B, four types of renal perfusion were reported. Among the 21 studies included, 10 reported on selective renal perfusion in cAAA OS, with several types of fluids described: (1) “enriched” Ringer’s solution, (2) “Custodiol” (Istidine-tryptophan-ketoglutarate or Custodiol HTKsolution), (3) other cold (4 °C) solutions (i.e., several combinations of 4 °C isotonic heparinized balanced salt solution containing mannitol, sodium bicarbonate, and methylprednisolone), and (4) warm blood. Thirty-day mortality for patients in group A was 4.25% (107/2516) vs. 4.29% (137/3192) in group B. The reported incidence of AKI and new onset of dialysis was, respectively, 22.14% (557/2516) and 5.45% (137/2516) for group A and 22.49% (718/3192) and 4.32% (138/3192) for group B. A total of 579 patients presented with chronic kidney disease (CKD) at admission across all studies, which included 350 (13.91%) in group A vs. 229 (7.17%) in group B. Acute kidney injury, 30-day mortality, and new-onset dialysis rate were reported in four subgroups: (1) In the “Ringer” group, 30-day mortality was 2.52% (3/113), AKI affected 27.73% (33/119) of patients, and the new-onset dialysis rate was 2.52% (3/113). (2) In the “Custodiol” group, 30-day mortality was 3.70% (3/81), AKI affected 20.17% (24/81) of patients, and the new-onset dialysis rate was 2.46% (2/81). (3) In the “cold solutions” group (i.e., NaCl and mannitol), 30-day mortality was 4.38% (130/2966), AKI affected 21.81% (647/2966) of patients, and the new-onset dialysis rate was 4.48% (133/2966). (4) In the “Warm blood” group, 30-day mortality was 3.85% (1/26), AKI affected 53.84% (14/26) of patients, and the new-onset dialysis rate was 0% (0/26). Conclusions: This systematic review highlights the lack of standard definitions for AKI, CKD, and the type of renal perfusion. Despite similar results in terms of AKI and 30-day mortality, renal perfusion seems to be protective of the new-onset hemodialysis rate. Moreover, Custodiol appears to have lower rates of AKI and hemodialysis than the other perfusion types. A prospective randomized controlled trial to perform further subgroup analysis and research the various types of renal perfusion may be necessary to identify possible benefits.